Sales +2% to 20.34B kroner, slightly missing consensus.
Excluding the impact of forex fluctuations, sales +7% in local currencies.
Novo Nordisk lowered its FY sales-growth guidance in local currencies to 7-10% from a prior forecast of 8-11%. The insulin company maintained its outlook for operating-profit growth of 10%.
Earnings were hampered by Express Scripts excluding Novo's Victoza and NovoLog diabetes treatments from its "preferred drug" list in January.
Share are -3.2% in Copenhagen. (PR)